Cidara Therapeutics Inc Stock
Your prediction
Cidara Therapeutics Inc Stock
Our community identified positive and negative aspects for Cidara Therapeutics Inc stock for the coming years. 1 users see the criterium "Revenue growth" as a plus for the Cidara Therapeutics Inc stock. On the other hand our users think that "Company culture" could be a problem in the future.
Pros and Cons of Cidara Therapeutics Inc in the next few years
Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
M***** P*******
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cidara Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cidara Therapeutics Inc | - | - | - | - | - | - | - |
| Larimar Therapeutics Inc. | -1.450% | -7.143% | -2.055% | -17.341% | -13.855% | -36.161% | -82.125% |
| aTyr Pharma Inc | -7.090% | 21.552% | 24.779% | -79.506% | 17.500% | -65.099% | -81.150% |
| Inotiv Inc. | 8.230% | -2.646% | -10.244% | -91.362% | -14.019% | -95.027% | -96.356% |
Comments
News
Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock?
According to a November 14, 2025 SEC filing, HighVista Strategies LLC initiated a new stake in Cidara Therapeutics (NASDAQ:CDTX), acquiring 70,904 shares worth $6.79 million as of September 30
Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer
On November 14, 2025, Bain Capital Life Sciences Investors, LLC disclosed a purchase of 520,310 shares of Cidara Therapeutics (NASDAQ:CDTX), increasing its position value by approximately $167.48
Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know.
Just prior to last week's takeover news, Cidara Therapeutics (NASDAQ: CDTX) was already one of the year's top-performing stocks. Trading in the mid-$20s at the start of 2025, by mid-November, this